Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. develops and commercializes medical device products for active healing, pain treatment, musculoskeletal care and surgical applications. The company organizes its portfolio around Pain Treatments, Restorative Therapies and Surgical Solutions, including products such as peripheral nerve stimulation devices, bone graft substitutes, ultrasonics, hyaluronic acid injections and ultrasound-based fracture healing therapies.
Recurring Bioventus news covers quarterly and annual results, financial guidance, revenue trends across its product areas and geographic markets, cash flow and margin performance, healthcare conference presentations, portfolio updates and regulatory developments affecting products such as Peripheral Nerve Stimulation offerings.
Bioventus (Nasdaq: BVS) announced the appointment of Mark Singleton as Senior Vice President and Chief Financial Officer, effective March 21, 2022. Singleton, who has over 20 years of experience in finance and operational roles, previously served at Teleflex, overseeing a $1.7 billion business. CEO Ken Reali stated that Singleton's experience and leadership qualities will enhance Bioventus' operational efficiencies and market leadership. Singleton expressed excitement about leveraging the company’s portfolio to drive growth and improve operating margins.
Bioventus (Nasdaq: BVS) announced it will report its financial results for Q4 and fiscal year 2021 on March 10, 2022, before the market opens. A conference call hosted by management will follow at 8:30 a.m. Eastern Time to discuss the results and provide a business update. The call can be accessed via phone or through a live webcast on the Investor Relations section of Bioventus' website. The webcast will be available for replay until March 9, 2023.
SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.
Bioventus (Nasdaq: BVS) announced preliminary revenue results for Q4 and full-year 2021, projecting revenues between $128.5 to $131.5 million for Q4, marking a 30% to 33% growth year-over-year, and $429 to $432 million for the full year, an increase of approximately 34%. CEO Ken Reali expressed pride in the team’s performance despite market challenges, highlighting strong growth in Pain Treatments and Bone Graft Substitutes. The company anticipates that recent acquisitions will meet or exceed expectations as it heads into 2022.
DURHAM, N.C., Dec. 28, 2021 – Bioventus (Nasdaq: BVS) announced that CEO Ken Reali will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 p.m. ET. The presentation will be accessible via a live webcast on the Bioventus investors website, and it will also be archived for later viewing. Bioventus is dedicated to providing innovative, clinically proven products that facilitate active healing and enhance patient recovery.
Bioventus (Nasdaq: BVS) has appointed Dr. Michelle McMurry-Heath to its Board of Directors, effective January 1, 2022. With over 20 years of experience in healthcare and regulatory roles, McMurry-Heath brings valuable insights to the company. Her previous positions include leading regulatory science at Johnson & Johnson and serving at the FDA. Bioventus aims to leverage her expertise in medical innovation and regulatory affairs to advance its offerings in pain treatment and restorative therapies. Company leadership expresses optimism about the strategic guidance she will provide.
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece, enhancing minimally invasive surgery with improved bone removal capabilities. This device, part of the neXus Ultrasonic Surgical Aspirator System, offers surgeons greater control and versatility. The launch is anticipated in 2022, with the system already commercialized in several countries. The BoneScalpel Access is indicated for use across various surgical specialties, indicating a broad application potential.
Bioventus (Nasdaq: BVS) announced a lease agreement to expand its operational and manufacturing space in Memphis, doubling its current area. The new facility, located at 7101 Goodlett Farms Parkway in Cordova, TN, features approximately 90,000 square feet, with 55,000 dedicated to manufacturing. This move is set for early Q3 2022 and will create an additional 40 jobs over five years. The expansion aligns with the company’s strategy for organic growth and vertical integration, enhancing its manufacturing capabilities.
Bioventus (Nasdaq: BVS) announced the departure of Greg Anglum from his role as CFO, effective immediately. Anglum will remain until a successor is identified. CEO Ken Reali praised Anglum for his contributions over five years, including during the IPO and recent acquisitions. The company reassures stakeholders that his departure is not due to business performance issues, reaffirming its financial guidance for 2021. Bioventus is actively seeking a new CFO to support its growth strategy.
Bioventus Inc. (Nasdaq: BVS) reported Q3 2021 net sales of $108.9 million, up 26.8% year-over-year, driven by strong commercial execution and acquisitions. The company generated a net loss of $2.3 million, down from net income of $8.0 million in Q3 2020. Adjusted EBITDA was $21.3 million, a decline of 7.7% year-over-year. Bioventus updated its full-year sales guidance to $425-$430 million, reflecting 32% to 34% growth. The company successfully integrated Bioness and completed the acquisition of Misonix, positioning itself for further growth in the healing innovations sector.